Aprea Therapeutics, Inc. (APRE) Financial Statements (2024 and earlier)

Company Profile

Business Address 3805 OLD EASTON ROAD
DOYLESTOWN, PA 18902
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments27,685,13130,995,71428,786,64733,112,60139,062,41547,651,774
Cash and cash equivalents27,685,13130,995,71428,786,64733,112,60139,062,41547,651,774
Other undisclosed current assets953,6701,022,8031,366,859361,1781,400,8372,393,096
Total current assets:28,638,80132,018,51730,153,50633,473,77940,463,25250,044,870
Noncurrent Assets
Operating lease, right-of-use asset    106,537170,967242,183
Property, plant and equipment1,6871,9122,32112,23720,25820,587
Restricted cash and investments40,180     
Other noncurrent assets    29,35129,35929,369
Total noncurrent assets:41,8671,9122,321148,125220,584292,139
TOTAL ASSETS:28,680,66832,020,42930,155,82733,621,90440,683,83650,337,009
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,694,1263,129,6232,512,2284,728,3006,129,7833,580,591
Employee-related liabilities1,572,3501,679,863577,149
Accounts payable1,131,197826,027842,7541,136,0643,989,7941,988,007
Accrued liabilities1,562,9292,303,5961,669,4742,019,886460,1261,015,435
Other undisclosed current liabilities1,256,6951,097,765688,858(730,161)1,554,4143,139,531
Total current liabilities:3,950,8214,227,3883,201,0863,998,1397,684,1976,720,122
Noncurrent Liabilities
Long-term debt and lease obligation:      28,061
Liabilities, other than long-term debt      
Liability for uncertainty in income taxes      
Operating lease, liability      28,061
Other undisclosed noncurrent liabilities      (28,061)
Total noncurrent liabilities:     28,061
Total liabilities:3,950,8214,227,3883,201,0863,998,1397,684,1976,748,183
Equity
Equity, attributable to parent23,418,78426,481,97825,643,67826,625,228(35,777,829)43,588,826
Common stock3,7313,7312,65552,23723,40121,974
Additional paid in capital335,485,317335,215,994330,060,836328,167,899261,795,121243,062,384
Accumulated other comprehensive loss(10,634,872)(10,561,452)(10,623,408)(10,240,645)(10,266,806)(10,424,461)
Accumulated deficit(301,435,392)(298,176,295)(293,796,405)(291,354,263)(287,329,545)(189,071,071)
Other undisclosed equity 1,311,0631,311,0631,311,0632,998,53768,777,468 
Total equity:24,729,84727,793,04126,954,74129,623,76532,999,63943,588,826
Other undisclosed liabilities and equity      
TOTAL LIABILITIES AND EQUITY:28,680,66832,020,42930,155,82733,621,90440,683,83650,337,009

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Operating expenses(3,901,369)(4,622,503)(2,651,628)(4,200,194)(98,465,531)(8,074,875)
Other undisclosed operating income249,688     
Operating loss:(3,651,681)(4,622,503)(2,651,628)(4,200,194)(98,465,531)(8,074,875)
Nonoperating income392,584242,613209,486175,476207,057274,393
Gain, foreign currency transaction, before tax      136,211
Other nonoperating income392,584242,613209,486175,476207,057138,182
Loss from continuing operations:(3,259,097)(4,379,890)(2,442,142)(4,024,718)(98,258,474)(7,800,482)
Loss before gain (loss) on sale of properties:(4,024,718)(98,258,474)(7,800,482)
Other undisclosed net loss      (136,211)
Net loss available to common stockholders, diluted:(3,259,097)(4,379,890)(2,442,142)(4,024,718)(98,258,474)(7,936,693)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(3,259,097)(4,379,890)(2,442,142)(4,024,718)(98,258,474)(7,936,693)
Comprehensive loss:(3,259,097)(4,379,890)(2,442,142)(4,024,718)(98,258,474)(7,936,693)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(73,420)61,956(382,763)26,161157,655(65,505)
Comprehensive loss, net of tax, attributable to parent:(3,332,517)(4,317,934)(2,824,905)(3,998,557)(98,100,819)(8,002,198)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: